Block listing Interim Review

AstraZeneca PLC

01 June 2023

 

1 June 2023 15:05 BST

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 1 June 2023

Name of applicant:		ASTRAZENECA PLC
Name of scheme:		ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME
Period of return:	From:	1 DECEMBER 2022	To:	31 MAY 2023
Balance of unallotted securities under scheme(s) from previous return:		4,818,134
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		341,752
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		4,476,382

Name of contact:	Hannah Tattersall
Telephone number of contact:	[phone]

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

END